COST-UTILITY ANALYSIS OF TOCILIZUMAB IN THE TREATMENT OF ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

被引：1
|
作者：
Vicente, C. [1 ]
Sabapathy, S. [1 ]
Formica, L. [2 ]
Maturi, B. [2 ]
Piwko, C. [1 ]
机构：
[1] PIVINA Consulting Inc, Mississauga, ON, Canada
[2] F Hoffmann La Roche & Co Ltd, Mississauga, ON, Canada
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1142
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A225 / A225
页数：1
相关论文
共 50 条
  • [41] DYNAMICS OF GROWTH IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB
    Seraya, V.
    Zholobova, E.
    Vitebskaya, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1205 - 1206
  • [42] Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis
    Yokota, Shumpei
    Tanaka, Toshio
    Kishimoto, Tadamitsu
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2012, 4 (06) : 387 - 397
  • [43] TOCILIZUMAB-EFFECTS ON GROWTH IMPAIRMENT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
    Miyamae, T.
    Nozawa, T.
    Kikuchi, M.
    Kizawa, T.
    Imagawa, T.
    Yokota, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 115 - 115
  • [44] EXPERIENCE WITH TOCILIZUMAB IN 29 PATIENTS WITH SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS
    Horneff, G.
    Onken, N.
    Hospach, A.
    Ganser, G.
    Huppertz, H. I.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 737 - 738
  • [45] Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
    De Benedetti, Fabrizio
    Brunner, Hermine I.
    Baildam, Eileen M.
    Burgos-Vargas, Ruben
    Horneff, Gerd
    Huppertz, Hans-Iko
    Minden, Kirsten
    Myones, Barry L.
    Onel, Karen
    Wang, Jianmei
    Bharucha, Kamal N.
    Lovell, Daniel J.
    Martini, Alberto
    Ruperto, Nicolino
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S114 - S114
  • [46] Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis
    De Benedetti, Fabrizio
    Ruperto, Nicolino
    Baildam, Eileen
    Burgos-Vargas, Ruben
    Horneff, Gerd
    Huppertz, Hans Iko
    Minden, Kirsten
    Myones, Barry L.
    Onel, Karen
    Wang, Jianmei
    Bharucha, Kamal N.
    Lovell, Daniel J.
    Martini, Alberto
    Brunner, Hermine
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S23 - S24
  • [47] Efficacy and safety of tocilizumab in 48-week treatment in children with systemic juvenile idiopathic arthritis
    Yokota, S.
    Imagawa, T.
    Mori, M.
    Ozawa, R.
    Miyamae, T.
    Ito, S.
    Aihara, Y.
    Nerome, Y.
    Imanaka, H.
    Takei, S.
    Kawano, Y.
    Iwata, N.
    Tomiita, M.
    Miyoshi, M.
    Murata, T.
    Umebayashi, H.
    Nishimoto, N.
    Kishimoto, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 110 - 110
  • [48] TOCILIZUMAB IN METHOTREXATE-NAIVE RHEUMATOID ARTHRITIS - A COST-UTILITY MODEL FOR SLOVAKIA
    Chang, S.
    Sawyer, L.
    Dejonckheere, F.
    Grichova, L.
    Diamantopoulos, A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A648 - A648
  • [49] Tocilizumab for rheumatoid and juvenile idiopathic arthritis
    Bongartz, Tim
    [J]. LANCET, 2008, 371 (9617): : 961 - 963
  • [50] Tocilizumab for treating juvenile idiopathic arthritis
    Turnier, Jessica L.
    Brunner, Hermine I.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (04) : 559 - 566
12345